Celgene Seeks Additional Oncologic To Leverage Thalomid Sales Force
Executive Summary
Celgene is planning to in-license an oncology product to be detailed alongside Thalomid (thalidomide), CEO John Jackson told the Biotechnology Industry Organization's CEO & Investor Conference in New York City Feb. 21.